XML 81 R66.htm IDEA: XBRL DOCUMENT v3.24.0.1
Fair Value of Financial Instruments - Narrative (Details) - USD ($)
$ in Thousands
12 Months Ended
Feb. 20, 2020
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Fair Value, Option, Quantitative Disclosures [Line Items]        
Revenues   $ 1,296,429 $ 935,061 $ 425,208
Contingent consideration liabilities   2,700 $ 111,600  
Change in fair value of the contingent financial asset and contingent financial liabilities   $ 9,300    
Fair Value, Net Derivative Asset (Liability), Recurring Basis, Still Held, Unrealized Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]   General and administrative    
Progenics        
Fair Value, Option, Quantitative Disclosures [Line Items]        
Royalty percentage     5.00%  
Aggregate cash payments percentage 40.00%      
Potential payments, high   $ 85,000    
Progenics | Cash Payments, 2022        
Fair Value, Option, Quantitative Disclosures [Line Items]        
Contingent consideration liabilities $ 100,000      
Progenics | Cash Payments, 2023        
Fair Value, Option, Quantitative Disclosures [Line Items]        
Contingent consideration liabilities $ 150,000      
Progenics | Net Sales Targets For Azedra        
Fair Value, Option, Quantitative Disclosures [Line Items]        
Potential payments, high   70,000    
Progenics | 1095 commercialization milestone        
Fair Value, Option, Quantitative Disclosures [Line Items]        
Potential payments, high   5,000    
Progenics | 1404 Commercialization Milestone        
Fair Value, Option, Quantitative Disclosures [Line Items]        
Potential payments, high   $ 10,000    
Royalty | Progenics        
Fair Value, Option, Quantitative Disclosures [Line Items]        
Revenues     $ 5,000